SRAVNITEL'NYY ANALIZ ANTIBAKTERIAL'NOY TERAPII OSTROGO TsISTITA


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Texto integral

Acesso é fechado

Bibliografia

  1. Foxman B., Barlow R., D’Arcy H. et al. Urinary tract infection: selfreported incidence and associated costs. Ann Epidemiol2000;10: 509515.
  2. Nickel J.C., Lee J.C., Grantmyre J.E. et al. Natural history of urinary tract infection in a primary care environment in Canada. Can J Urol2005;12: 2728-2737.
  3. Reeves D.S. Fosfomycin trometamol. J Antimicrob Chemother1994;34: 853-858.
  4. Gupta K. Emerging antibiotic resistance in urinary tract pathogens. Infect Dis Clin North Am2003;17: 243-259.
  5. Gagliotti C., Buttazzi R., Sforza S. et al. Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused byEscherichia coli. J Infect 2008;57: 179-184.
  6. Ho P.L., Wong R.C., Yip K.S. et al. Antimicrobial resistance in Escherichia coli outpatient urinary isolates from women: emerging multidrug resistance phenotypes.Diagn Microbiol Infect Dis2007;59: 439-445.
  7. Zahar J.R., Lortholary O., Martin C. et al. Addressing the challenge of extended-spectrumb-lactamases. Curr Opin Investig Drugs2009;10: 172-180.
  8. Patel S.S., Balfour J.A., Bryson H.M. Fosfomycin tromethamine: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.Drugs1997;53: 637-656.
  9. Roussos N., Karageorgopoulos D.E., Samonis G. et al. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents2009;34: 506-515.
  10. Warren J.W., Abrutyn E., Hebel J.R. et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis1999;29: 745-758.
  11. Falagas M.E., Giannopoulou K.P., Kokolakis G.N. et al. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008;46: 1069-1077.
  12. Falagas M.E., Kanellopoulou M.D., Karageorgopoulos D.E. et al. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin.Eur J Clin Microbiol Infect Dis2008;27: 439-443.
  13. Falagas M.E., Kastoris A.C., Karageorgopoulos D.E. et al. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of Systematic review 1875 JAC by guest on October 6, 2012 http://jac.oxfordjournals.org/ Downloaded from microbiological, animal and clinical studies.Int J Antimicrob Agents2009; 34: 111-120.
  14. Falagas M.E., Roussos N., Gkegkes I.D. et al. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs2009;18: 921-944.
  15. Nicolle L.E., Bradley S., Colgan R. et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults.Clin Infect Dis2005;40: 643-654.
  16. Rubin R.H., Shapiro E.D., Andriole V.T. et al. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration.Clin Infect Dis1992;15Suppl 1: S216-227.
  17. Moher D., Jadad A.R., Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care1996;12: 195-208.
  18. Moher D., Pham B., Jones Aet al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet1998;352: 609-613.
  19. Bozkurt O, Kara C., Akarsu S. et al. Comparison efficacy of single dose fosfomycin with ciprofloxacin in the treatment of urinary tract infection in symptomatic women.Turk Uroloji Dergisi2008;34: 360-362.
  20. Gupta K., Hooton T.M., Stamm W.E. Isolation of fluoroquinolone-resistant rectal Escherichia coliafter treatment of acute uncomplicated cystitis.J Antimicrob Chemother2005;56: 243-246.
  21. Stein G.E. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther1999;21: 1864-1872.
  22. Minassian M.A., Lewis D.A., Chattopadhyay D. et al. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents 1998;10:39-47.
  23. Richaud C. Le traitement monodose de la cystite non compliquee chez la femme propos d’un essai fosfomycine trometamol (Monuril w) versus pefloxacine.Med Mal Infect1995;25: 154-159.
  24. Elhanan G., Tabenkin H., Yahalom R. et al. Single-dose fosfomycin trometamol versus 5-day cephalexin regimen for treatment of uncomplicated lower urinary tract infections in women. Antimicrob Agents Chemother1994;38: 2612-2642.
  25. Van Pienbroek E., Hermans J., Kaptein A.A. et al. Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women.Pharm World Sci1993;15: 257-262.
  26. Cortes R., Pascual T., Lou Arnal S. et al. Single oral dose of phosphomycin trometamol versus pipemidic acid and norfloxacin intreating uncomplicated low-level urinary tract infections. Aten Primaria 1992;10: 1007-1112.
  27. de Jong Z., Pontonnier F., Plante P. Single-dose fosfomycin trometamol (Monuril) versus multiple-dose norfloxacin: results of a multicenter study in females with uncomplicated lower urinary tract infections. Urol Int 1991;46: 344-348.
  28. Boerema J.B., Willems F.T. Fosfomycin trometamol in a single dose versus norfloxacin for seven days in the treatment of uncomplicated urinary infections in general practice. Infection 1990; 18 Suppl 2: S80-88.
  29. Crocchiolo P. Single-dose fosfomycin trometamol versus multiple-dose cotrimoxazole in the treatment of lower urinary tract infections in general practice. Multicenter Group of General Practitioners. Chemotherapy1990;36Suppl 1: 37-40.
  30. Harvard Davis R., O’Dowd T.C., Holmes W. et al. A comparative doubleblind randomised study of single dose fosfomycin trometamol with trimethoprim in the treatment of urinary tract infections in general practice. Chemotherapy1990;36Suppl 1: 34-36.
  31. Naber K.G., Thyroff-Friesinger U. Fosfomycin trometamol versus ofloxacin/co-trimoxazole as single dose therapy of acute uncomplicated urinary tract infection in females: a multicentre study. Infection1990;18Suppl 2: S70-76.
  32. Neu H.C. Fosfomycin trometamol versus amoxycillin-single-dose multicenter study of urinary tract infections.Chemotherapy1990;36 Suppl 1: 19-23.
  33. Reynaert J., Van Eyck D., Vandepitte J. Single dose fosfomycin trometamol versus multiple dose norfloxacin over three days for uncomplicated UTI in general practice. Infection 1990; 18 Suppl 2: S77-79.
  34. Selvaggi F.P., Ditonno P., Traficante A et al. Fosfomycin trometamol (Monuril) versus norfloxacin in single dose for adult female uncomplicated UTIs: multicenter randomized, double-blind study. Chemotherapy1990;36Suppl 1: 31-33.
  35. Caramalli S., Amprimo M.C., Cavalli G. et al. Effect and pharmacokinetics of netilmicin given as bolus intramuscular administration: an open comparative trial versus amikacin and fosfomycin in elderly patients affected by urinary tract infections.Int J Clin Pharmacol Res 1991;11: 55- 65.
  36. Cooper J., Raeburn A., Brumfitt W. et al. Single dose and conventional treatment for acute bacterial and non-bacterial dysuria and frequency in general practice. Infection1990;18: 65-69.
  37. Ferraro G, Ambrosi G, Bucci L. et al. Fosfomycin trometamol versus norfloxacin in the treatment of uncomplicated lower urinary tract infections of the elderly. Chemotherapy1990;36Suppl 1: 46-49.
  38. Estebanez A., Pascual R., Gil V. et al. Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy.Eur J Clin Microbiol Infect Dis2009;28: 1457-1464.
  39. Bayrak O., Cimentepe E., Inegol I. et al. Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimester of pregnancy? Int Urogynecol J Pelvic Floor Dysfunct 2007;18: 525-529.
  40. Krcmery S., Hromec J., Demesova D. Treatment of lower urinary tract infection in pregnancy. Int J Antimicrob Agents 2001; 17: 279-282.
  41. Zinner S. Fosfomycin trometamol versus pipemidic acid in the treatment of bacteriuria in pregnancy. Chemotherapy1990;36Suppl 1:50-52.
  42. Thoumsin H., Aghayan M., Lambotte R. Single dose fosfomycin trometamol versus multiple dose nitrofurantoin in pregnant women with bacteriuria: preliminary results. Infection 1990; 18 Suppl 2: S94-97.
  43. Principi N., Corda R., Bassetti D. et al. Fosfomycin trometamol versus netilmicin in children’s lower urinary tract infections. Chemotherapy 1990;36Suppl 1: 41-45.
  44. Careddu P., Borzani M., Scotti L. et al. Treatment of lower urinary tract infections in children: single dose fosfomycin trometamol versus pipemidic acid.Chemioterapia1987;6: 290-294.
  45. Varese L.A. Trometamol salt of fosfomycin versus netilmicin: randomized multicenter study in children’s lower urinary tract infections. Eur Urol1987;13Suppl 1: 119-121.
  46. Kumon H., Ono N., Iida M. et al. Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm. Antimicrob Agents Chemother1995;39: 1038-1044. Systematic review 1876 by guest on October 6, 2012 http://jac.oxfordjournals.org/ Downloaded from
  47. Mikuniya T., Kato Y., Ida T. et al. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J Infect Chemother 2007;13: 285-290.
  48. Marchese A., Bozzolasco M., Gualco L. et al. Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms. Int J Antimicrob Agents2003;22Suppl 2: 95-100.
  49. Borsari A.G., Bucher B., Brazzola P. et al. Susceptibility of Escherichia coli strains isolated from outpatient children with community-acquired urinary tract infection in southern Switzerland.Clin Ther2008; 30: 2090-205.
  50. Romero R., Oyarzun E., Mazor M. et al. Meta-analysis of the relationship between asymptomatic bacteriuria and preterm delivery/low birth weight. Obstet Gynecol1989;73: 576-582.
  51. Dore-Bergeron M.J., Gauthier M., Chevalier I. et al. Urinary tract infections in 1- to 3-month-old infants: ambulatory treatment with intravenous antibiotics. Pediatrics2009;124: 16-22.
  52. Maraki S., Samonis G., Rafailidis P.I. et al. Susceptibility of urinary tract bacteria to fosfomycin.Antimicrob Agents Chemother2009;53: 4508-4510.
  53. Falagas M., Kastoris A., Kapaskelis A.et al. Fosfomycin for the treatment of multidrug-resistant Enterobacteriaceae infections: a systematic review. Lancet Infect Dis2010;10Suppl 1: 43-50.
  54. http://www.accessdata.fda.gov/drugsatfda_docs/ label/2008/050717s005lbl.pdf.
  55. Mayama T., Yokota M., Shimatani I. et al. Analysis of oral fosfomycin calcium (Fosmicin) side-effects after marketing. Int J Clin Pharmacol Ther Toxicol1993;31: 77-82.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2013

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies